Literature DB >> 25089593

Administration of anti-thymocyte globulin: a comparison of two protocols.

A B Clemmons1, M E Hartranft2, V Kota3, J Pantin3, F T Awan4, H Salman3, A P Jillella5.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25089593     DOI： 10.1038/bmt.2014.174

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  7 in total

1.  Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation.

Authors:  J Andersen; C Heilmann; N Jacobsen; C Nielsen; K Bendtzen; K Müller
Journal:  Bone Marrow Transplant       Date:  2006-04       Impact factor: 5.483

2.  Antihuman thymocyte globulin for prophylaxis of graft-versus-host disease. A randomized trial in patients with leukemia treated with HLA-identical sibling marrow grafts.

Authors:  P L Weiden; K Doney; R Storb; E D Thomas
Journal:  Transplantation       Date:  1979-04       Impact factor: 4.939

3.  Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression.

Authors:  R D Guttmann; P Caudrelier; G Alberici; J L Touraine
Journal:  Transplant Proc       Date:  1997-11       Impact factor: 1.066

Review 4.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

5.  Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

Authors:  Jürgen Finke; Wolfgang A Bethge; Claudia Schmoor; Hellmut D Ottinger; Matthias Stelljes; Axel R Zander; Liisa Volin; Tapani Ruutu; Dominik A Heim; Rainer Schwerdtfeger; Karin Kolbe; Jiri Mayer; Johan A Maertens; Werner Linkesch; Ernst Holler; Vladimir Koza; Martin Bornhäuser; Hermann Einsele; Hans-Jochem Kolb; Hartmut Bertz; Matthias Egger; Olga Grishina; Gérard Socié
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

6.  Bone marrow graft in man after conditioning by antilymphocytic serum.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; J Choay; P Trolard; M Schneider; M Hayat; J R Schlumberger; C Jasmin
Journal:  Br Med J       Date:  1970-04-18

7.  Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

Authors:  A O Gaber; M R First; R J Tesi; R S Gaston; R Mendez; L L Mulloy; J A Light; L W Gaber; E Squiers; R J Taylor; J F Neylan; R W Steiner; S Knechtle; D J Norman; F Shihab; G Basadonna; D C Brennan; E E Hodge; B D Kahan; L Kahan; S Steinberg; E S Woodle; L Chan; J M Ham; T J Schroeder
Journal:  Transplantation       Date:  1998-07-15       Impact factor: 4.939
  7 in total
  1 in total

1.  Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII.

Authors:  Athena L Russell; Chengyu Prince; Taran S Lundgren; Kristopher A Knight; Gabriela Denning; Jordan S Alexander; Jaquelyn T Zoine; H Trent Spencer; Shanmuganathan Chandrakasan; Christopher B Doering
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.